Search

Displaying results 2931 - 2940 of 6951 in total
  1. Drug

    Hydroxypropyl cellulose

    go.drugbank.com/drugs/DB00840
    Approved

    Lacrisertis a formulation of hydroxypropyl cellulose that is used for artificial tears. … syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for

  2. Drug

    Cyclopentolate

    go.drugbank.com/drugs/DB00979
    Approved

    A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.

  3. Drug

    Ferric maltol

    go.drugbank.com/drugs/DB15598
    ApprovedInvestigational

    [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … [A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.

  4. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal

  5. Drug

    4-(Isopropylamino)diphenylamine

    go.drugbank.com/drugs/DB14195
    Approved

    4-(Isopropylamino)diphenylamine, also known as IPPD, is a chemical compound commonly used as an antiozonant in rubbers, particularly those used for tires. It is also a known allergen.

  6. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248870] Along with [human interferon beta], [teriflunomide], and [dimethyl fumarate], glatiramer acetate is a first-line drug for patients with MS.

  7. Drug

    Quinethazone

    go.drugbank.com/drugs/DB01325
    Approved

    Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.

  8. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.

  9. Target

    P2Y purinoceptor 2

    go.drugbank.com/bio_entities/BE0002401
    TargetHumans

    Receptor for ATP and UTP coupled to G proteins that activate a phosphatidylinositol-calcium second messenger system. The affinity range is UTP = ATP > ATP-gamma-S >> 2-methylthio-ATP = ADP

    Synonyms: ATP receptor, P2U receptor 1Function: A1 adenosine receptor binding
  10. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840). … In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713].

    Categories: Experimental Unapproved Treatments for COVID-19